Cholangiocarcinoma
📧 Sign up to get email alerts when something new happens for Cholangiocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2023-05-03Clinical Trial Update: Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery [Phase 4]
A Phase 4 clinical trial evaluating anesthetic agents and acute kidney injury after liver resection has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Treatment for Bile Duct Cancer in the Liver [Phase 2]
Phase 2 clinical trial update for a treatment targeting cholangio carcinoma (bile duct cancer) in the liver; study completed.
-
CLINICAL_TRIALS trial_result · 2023-04-13Clinical Trial Update: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) [Phase 3]
Phase 3 TOPAZ-1 trial results for durvalumab in combination with gemcitabine/cisplatin in first-line biliary tract cancer have been posted.
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 [Phase 1, Phase 2]
Phase 1/2 trial update for IMM2902 in patients with HER2-expressing advanced solid tumors including advanced solid tumors, advanced lung can…
-
CLINICAL_TRIALS trial_result · 2023-03-29Clinical Trial Update: Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors [Phase 2]
Phase 2 trial evaluating lenvatinib combined with pembrolizumab in advanced hepatobiliary tumors has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers [Phase 2]
Phase 2 trial of perioperative MVT-5873, a CA 19-9 epitope–targeting monoclonal antibody, in operable CA 19-9–producing pancreatic cancers, …
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: A Study of ICP-192 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update for ICP-192 in advanced solid tumors and urothelial carcinoma (Phase 1/2). Status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) [Phase 2]
Phase 2 FIGHT-202 trial updates show efficacy and safety data for pemigatinib in advanced/metastatic or surgically unresectable cholangiocar…
-
EMA withdrawal · 2023-01-30EMA Application withdrawn: Febseltiq (Infigratinib monophosphate) — Helsinn Birex Pharmaceuticals Ltd
Application withdrawn for Febseltiq (Infigratinib monophosphate) by Helsinn Birex Pharmaceuticals Ltd in relation to cholangiocarcinoma.
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) [Phase 1, Phase 2]
Open-label, dose-escalation study of pemigatinib in advanced malignancies (FIGHT-101) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-09Clinical Trial Update: Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma [Phase 2]
Phase 2 clinical trial assessing radiotherapy with concurrent gemcitabine and oxaliplatin in locally advanced, unresectable non-metastatic p…
-
CLINICAL_TRIALS trial_result · 2022-12-07Clinical Trial Update: Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer [Phase 2]
Phase 2 clinical trial update on durvalumab combined with neoadjuvant chemotherapy for resectable biliary tract cancer.
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 trial comparing adjuvant capecitabine to a gemcitabine plus cisplatin regimen in resected extrahepatic cholangiocarcinoma has comp…
-
CLINICAL_TRIALS trial_result · 2022-10-21Clinical Trial Update: Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma [Phase 3]
Phase 3 trial evaluating chemotherapy alone versus chemotherapy with radiation for unresectable cholangiocarcinoma; current status not speci…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: Trial of IRE in Cholangiocarcinoma [Phase 2]
Phase 2 trial update for irreversible electroporation (IRE) in cholangiocarcinoma has completed with results posted in 2022.
-
FDA approval · 2022-08-26FDA Approved: PEMAZYRE — Supplemental Application (Incyte Corporation)
FDA approved a supplemental application for Pemazyre (pemigatinib) filed by Incyte Corporation, indicating an update to the drug's labeling …
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence [Phase 1, Phase 2]
A clinical trial exploring adjuvant PD-1 antibody in combination with capecitabine for intrahepatic cholangiocarcinoma at high risk of recur…
-
CLINICAL_TRIALS trial_result · 2022-07-15Clinical Trial Update: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma [Phase 2]
Phase II, single-arm study of BGJ398 in advanced cholangiocarcinoma with FGFR2 mutation was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC [Phase 2, Phase 3]
Phase 2/3 trial evaluating gemcitabine plus cisplatin with or without bintrafusp alfa (M7824) in first-line biliary tract cancer; study term…
-
CLINICAL_TRIALS trial_result · 2022-04-13Clinical Trial Update: Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) [Phase 3]
Phase 3 study ClarIDHy evaluating ivosidenib in IDH1-mutated advanced cholangiocarcinoma has completed enrollment with results posted in 202…
-
CLINICAL_TRIALS trial_result · 2022-03-24Clinical Trial Update: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) [Phase 2]
Phase 2 pilot study evaluating combined immune checkpoint inhibition with ablative therapies in hepatocellular carcinoma and biliary tract c…
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors [Phase 2]
Phase 2 trial evaluating tisleizumab with lenvatinib and XELOX in first-line treatment of advanced unresectable biliary tract tumors.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors [Phase 1]
Phase 1 trial evaluating LMB-100 with tofacitinib in previously treated mesothelin-expressing solid tumors, including pancreatic adenocarcin…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. [Phase 2]
Phase 2 trial evaluating sintilimab (PD-1 inhibitor) combined with capecitabine as adjuvant treatment after radical resection of cholangioca…
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) [Phase 2]
Phase 2 trial of M7824 monotherapy in second-line biliary tract cancers (cholangiocarcinoma and gallbladder cancer) has completed with resul…